✦ LIBER ✦

Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

✍ Scribed by Kyunghee Burkitt; Mats Ljungman

Book ID: 119901984
Publisher: BioMed Central
Year: 2008
Tongue: English
Weight: 801 KB
Volume: 7
Category: Article
ISSN: 1476-4598
DOI: 10.1186/1476-4598-7-24

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Compromised Fanconi anemia response due

Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines

✍ Kyunghee Burkitt; Mats Ljungman 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 378 KB

Variation in cisplatinum sensitivity is

Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines

✍ Eric R. Snyder; Justin L. Ricker; Zhong Chen; Carter Van Waes 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Hypoxia disrupts the Fanconi anemia path

Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T

✍ Chantal H.M.A. Ramaekers; Twan van den Beucken; Alice Meng; Shaqil Kassam; John 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 449 KB

Antisense Cyclin D1 Enhances Sensitivity

Antisense Cyclin D1 Enhances Sensitivity of Head and Neck Cancer Cells to Cisplatin

✍ Marilene B. Wang; Helena T. Yip; Eri S. Srivatsan 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 715 KB

Cisplatin sensitization to radiotherapy

Cisplatin sensitization to radiotherapy of squamous cell carcinomas of the head and neck

✍ Bruce Leipzig 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 485 KB

Intrinsic differences in cisplatin sensi

Intrinsic differences in cisplatin sensitivity of head and neck cancer cell lines: Correlation to lysosomal pH

✍ Cathrine Nilsson; Karin Roberg; Roland C. Grafström; Karin Öllinger 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 390 KB 👁 2 views

## Abstract ## Background Cisplatin treatment is beneficial for approximately 20% of patients with head and neck squamous cell carcinoma (HNSCC). Tools to predict the clinical outcome and evaluate intrinsic cisplatin sensitivity are, therefore, required. ## Methods Cisplatin sensitivity, lysosom